Insight Molecular Diagnostics (IMDX) revenue breakdown
By product, Laboratory Services is the largest at 99% of fiscal 2025 revenue, growing 66% a year over 2 years.
By region, United States is the largest at 99% of fiscal 2025 revenue, growing 109% a year over 2 years.
Revenue by product
Fiscal years, as Insight Molecular Diagnostics reports them in its 10-K filings; fiscal 2025 total $4M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Laboratory Services | $1M | $2M | $4M | 99% |
| Kitted Products | — | — | $24,000 | 1% |
| Laboratory Developed Test Services | $36,000 | $22,000 | — | — |
Revenue by region
Fiscal years, as Insight Molecular Diagnostics reports them in its 10-K filings; fiscal 2025 total $4M.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| United States | $923,000 | $2M | $4M | 99% |
| Europe | — | $18,000 | $24,000 | 1% |
| Asia Pacific | $160,000 | $145,000 | — | — |
| United Kingdom | $409,000 | $45,000 | — | — |
| Spain | $11,000 | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMDX.
Open IMDX in InvestinglyQuestions
Where does Insight Molecular Diagnostics make its money?
In fiscal 2025, by product: Laboratory Services $4M, Kitted Products $24,000.
From Insight Molecular Diagnostics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.